Early Kidney Replacement Therapy × Freedom from Kidney Replacement Therapy at 90 Days — Evidence Checklist

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Efficacy comparison and presentation of stored materialDoes the selected KRT-independence question differ from the parent mortality verdict?Required	The selected question is 'freedom from kidney replacement therapy at 90 days'; its original D grade/note says dependence among survivors was higher in the early group. Subclaim points, status and axes are absent; parent D34, Caution and the 90-day mortality verdict/axes are separate. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Do not fill absent subclaim values with parent values or create a new grade. Existing content review remains incomplete.	Distinguish the subclaim D grade/note and absent points/status/axes from parent D34/axes	Proposal: Separate the sources of the independence question and mortality verdict. No new research, calculation or trial was performed.
2	Partly verified	Full text not readStored summary read	N02 · Efficacy comparison and presentation of stored materialWhat values are provided for the original 'independence' question?Required	The original STARRT-AKI research description reports 90-day dependence among survivors as 85/814 (10.4%) versus 49/815 (6.0%), RR1.74 (95% CI1.24~2.43). Do not newly convert dependence values into independence rates, independence RR or recovery rates. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Direct independence events, proportions and definitions, and details of the original dependence endpoint, are unverified. Existing content review remains incomplete.	Distinguish KRT independence from the survivor dependence actually reported	Proposal: Link the independence question with the reported dependence values. No new research, calculation or trial was performed.
3	Partly verified	Full text not readStored summary read	N03 · Efficacy comparison and presentation of stored materialWhat denominators are survivor 814/815 and mortality-analysis 1465/1462?Required	Dependence 85/814 versus 49/815 uses the original survivor-conditional denominators. Mortality 643/1465 versus 639/1462 uses different analysis denominators; do not newly calculate survivors/missing counts from them to replace the dependence denominators. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Eligibility/exclusions, missingness/follow-up and reasons connecting the survivor-dependence denominators are unverified. Existing content review remains incomplete.	Separate the survival condition/dependence analysis from the overall mortality analysis	Proposal: Link the entire assigned/mortality population and survivor-conditional outcomes. No new research, calculation or trial was performed.
4	Partly verified	Full text not readStored summary read	N04 · Efficacy comparison and presentation of stored materialWhat comparison direction is represented by dependence RR1.74 and its CI?Required	Original survivor dependence increased from standard 6.0% to early 10.4%, RR1.74 (1.24~2.43). Do not turn it into an effect improving independence, mortality RR, a reciprocal or an absolute risk difference. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The original dependence P value, model/adjustment and event-definition/timing details are unverified. Existing content review remains incomplete.	Distinguish early versus standard dependence RR/CI from independence/absolute effects	Proposal: Document the original comparison direction, interval and endpoint specification. No new research, calculation or trial was performed.
5	Partly verified	Full text not readStored summary read	N05 · Efficacy comparison and presentation of stored materialIs a survivor-conditional result the same as kidney recovery in all patients?Required	The original report concerns KRT dependence at 90 days among survivors. Do not calculate kidney recovery in all randomized patients, a pure causal dependence effect independent of death or a new survival/independence composite outcome. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Survivor-conditional selection, handling of death, composite/competing-event analyses and individual trajectories are unverified. Existing content review remains incomplete.	Survivor selection, death as a competing event and randomized/conditional estimation	Proposal: Document conditional and whole-population outcomes separately. No new research, calculation or trial was performed.
6	Partly verified	Full text not readStored summary read	N06 · Efficacy comparison and presentation of stored materialWhat were the actual STARRT-AKI population and initiation strategies?Required	Original STARRT-AKI compares initiation strategies before absolute indications in severe acute kidney injury. The standard group also started when indications arose; this is a historical condition, with no treatment initiation/delay or suitability instructions. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact severity/eligibility, early/standard timing and exclusion/concomitant-treatment details are unverified. Existing content review remains incomplete.	Severe AKI, early/standard initiation before absolute indications and eligibility/exclusions	Proposal: Link population and strategy conditions. No new research, calculation or trial was performed.
7	Partly verified	Full text not readStored summary read	N07 · Efficacy comparison and presentation of stored materialHow do 3019 randomized and 2927 analyzed participants differ?Required	The original account states that STARRT-AKI randomized 3019 at 168 sites in 15 countries and analyzed 2927 by modified ITT after postrandomization ineligibility, consent withdrawal and other exclusions. Do not newly calculate exclusion counts/proportions. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Arm-specific exclusions/missingness, dependence-analysis inclusion criteria and the entire follow-up path are unverified. Existing content review remains incomplete.	Postrandomization ineligibility/consent withdrawal, denominators and modified ITT scope	Proposal: Link randomized, mortality and survivor analysis populations. No new research, calculation or trial was performed.
8	Partly verified	Full text not readStored summary read	N08 · Efficacy comparison and presentation of stored materialWhat were the 90-day dependence assessment and discontinuation/restart rules?Required	The original reports dependence among 90-day survivors. Do not newly attach definitions involving treatment on a specific day, a preceding period, discharge status or long-term dependence. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Dependence/independence assessment rules, treatment discontinuation/restart and follow-up methods/missingness are unverified. Existing content review remains incomplete.	Definitions of KRT status, assessment timing/duration and collection/follow-up	Proposal: Document KRT status and the timing/assessment specification. No new research, calculation or trial was performed.
9	Partly verified	Full text not readStored summary read	N09 · Efficacy comparison and presentation of stored materialHow does the open-label design relate to dependence assessment?Required	The original describes centralized computer-generated allocation, an open-label design, a primary 90-day all-cause mortality endpoint and B0 evidence. Do not transfer the nature of mortality measurement to blinding of KRT continuation/discontinuation decisions. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Dependence assessors/blinding, actual treatment decisions and follow-up procedures are unverified. Existing content review remains incomplete.	Distinguish allocation concealment/openness from mortality/KRT decisions	Proposal: Link design with endpoint-specific measurement/decisions. No new research, calculation or trial was performed.
10	Partly verified	Full text not readStored summary read	N10 · Efficacy comparison and presentation of stored materialWhat was the prespecified endpoint hierarchy for dependence?Required	The original prespecified primary endpoint was all-cause mortality at 90 days. Do not upgrade survivor KRT dependence to the primary endpoint or newly assign a different independence objective or power. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Prespecification/hierarchy of the dependence endpoint, multiple comparisons and model/plan are unverified. Existing content review remains incomplete.	Primary mortality, dependence/safety and multiplicity/prespecified analysis	Proposal: Link the primary timepoint/endpoint and secondary dependence analysis. No new research, calculation or trial was performed.
11	Partly verified	Full text not readStored summary read	N11 · Efficacy comparison and presentation of stored materialDoes overall 90-day mortality differ from the selected independence outcome?Required	The original mortality values are 643/1465 (43.9%) versus 639/1462 (43.7%), RR1.00 (.93~1.09), P=.92. Do not turn them into dependence incidence, zero independence effect, equivalence or conditional kidney-recovery verification. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Individual mortality/dependence linkage, joint estimation and precision details of the selected analysis are unverified. Existing content review remains incomplete.	Separate context of original 643/1465, 639/1462 and RR1.00/CI/P	Proposal: Document hard mortality and survivor-conditional dependence separately. No new research, calculation or trial was performed.
12	Partly verified	Full text not readStored summary read	N12 · Efficacy comparison and presentation of stored materialHow do actual treatment exposure/crossover relate to dependence?Required	The original study-condition description states that the early group had more treatment exposure and 90-day dependence. Do not arbitrarily fill exposure quantity/timing, procedure type/discontinuation or establish dependence causality from increased exposure alone. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Denominators/timing of actual exposure/crossover, procedure types, concomitant treatment and discontinuation/restart are unverified. Existing content review remains incomplete.	Greater early-group exposure, indication-based standard initiation and actual pathways	Proposal: Link assigned strategies with actual exposure/dependence. No new research, calculation or trial was performed.
13	Partly verified	Full text not readStored summary read	N13 · Efficacy comparison and presentation of stored materialDoes ELAIN's positive mortality result directly answer 90-day independence?Required	The original ELAIN context is a German single-center trial of 231 reporting 90-day mortality of 39.3% versus 54.7%, HR.66, P=.03. Do not transfer it to direct values or a replication trial for the selected KRT-independence question. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. ELAIN 90-day independence/dependence definitions, values, denominators, CI and conditions are unverified in this preserved summary. Existing content review remains incomplete.	Context of 231 participants, one center, mortality 39.3/54.7% and HR/P	Proposal: Separate mortality context from the selected independence endpoint. No new research, calculation or trial was performed.
14	Partly verified	Full text not readStored summary read	N14 · Efficacy comparison and presentation of stored materialDoes AKIKI 60-day survival directly answer 90-day independence?Required	The original AKIKI context is no 60-day survival difference among 620 randomized/619 analyzed at 31 French ICUs. Do not change 60-day survival into 90-day KRT independence or a replicated dependence RR1.74. S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. AKIKI independence/dependence timing, values, denominators and precision are unverified. Existing content review remains incomplete.	Scope of 620 randomized/619 analyzed, 31 ICUs and 60-day survival	Proposal: Document differences in timing/endpoints. No new research, calculation or trial was performed.
15	Partly verified	Full text not readStored summary read	N15 · Efficacy comparison and presentation of stored materialHow do different early definitions and populations across the three trials relate?Required	The original account says early/delayed definitions and severity differed across trials. Do not certify ELAIN/AKIKI/STARRT mortality context as unique replication of the same dependence endpoint. S01 S02 S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact strategy/eligibility/timing differences, dependence outcomes, effect modification and reasons for conflicting results are unverified. Existing content review remains incomplete.	Institutions/patients/timing, strategy definitions and the history of conflicting original results	Proposal: Document relationships across different strategies/populations/endpoints. No new research, calculation or trial was performed.
16	Partly verified	Full text not readStored summary read	N16 · Efficacy comparison and presentation of stored materialAre the same trial and parent mortality/independence questions and reports kept from being summed?Required	This sheet's STARRT survivor data and parent mortality context are different conditions/endpoints of the same trial/population. Do not sum the three bibliographic entries, analysis denominators, timepoints or different questions into new independent trials/total participants. S01 S02 S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Unique trial, participant and independent-replication totals have not been confirmed and remain unrecorded. Existing content review remains incomplete.	Shared reports/trials/populations, different endpoints and units	Proposal: Record shared/overlapping relationships separately. No new research, calculation or trial was performed.
17	Partly verified	Full text not readStored summary read	N17 · Efficacy comparison and presentation of stored materialWhat were STARRT's mixed support and Alere's in-kind contribution?Required	The original describes two CIHR grants, CIHR-Baxter industry partnership, NHMRC, New Zealand HRC, NIHR HTA and Alere's in-kind Triage MeterPro devices for NGAL. Do not turn this into free treatment equipment, absence of company roles/COI or independence verification. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Support contracts, company/employee authors, analysis/manuscript decision rights and COI are unverified. Existing content review remains incomplete.	Distinguish public/industry partnership and in-kind measurement devices from actual roles/COI	Proposal: Document funding/measurement-device support and actual roles. No new research, calculation or trial was performed.
18	Partly verified	Full text not readStored summary read	N18 · Efficacy comparison and presentation of stored materialDoes ELAIN/AKIKI support verify independence for the dependence question?Required	Preserve original ELAIN institutional/nonprofit support and AKIKI French Ministry of Health funding. Funding names alone do not verify absence of product/company/employee authors or COI, or independent replication of the dependence endpoint. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Specific funding/product support, contributions, employees/COI and dependence outcomes are unverified. Existing content review remains incomplete.	Institutional/nonprofit support, French Ministry of Health and detailed roles	Proposal: Separate each trial's funding from actual roles. No new research, calculation or trial was performed.
19	Partly verified	Full text not readStored summary read	N19 · Efficacy comparison and presentation of stored materialWere registry IDs and prespecified independence/dependence analyses actually read?Required	Preserve each original registry ID. Do not transfer the historical account of the STARRT primary mortality endpoint agreeing with its registry into registry/plan reading here or prespecified dependence fulfillment. S01 S02 S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Registry-change history, protocols/SAP and dependence hierarchy/missing-data plans remain unread. Existing content review remains incomplete.	Original DRKS00004367, NCT01932190/02568722 identifiers and plans	Proposal: Link endpoint-specific prespecified plans with report versions. No new research, calculation or trial was performed.
20	Partly verified	Full text not readStored summary read	N20 · Harm-information gaps supplementing the efficacy tableHow do KRT complications and dependence represent different harm information?Supplementary	The original safety description discusses possible hypotension, infection, bleeding and vascular-access complications, alongside increased survivor dependence. Do not turn these into actual individual event counts/cause verification or zero overall risk. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Definitions/collection, denominators, exposure/timing, CI and relatedness of each complication are unverified. Existing content review remains incomplete.	Hypotension/infection/bleeding/access complications and actual event reports	Proposal: Document dependence separately from other safety events. No new research, calculation or trial was performed.
21	Partly verified	Full text not readStored summary read	N21 · Harm-information gaps supplementing the efficacy tableWhat is the scope of survivor follow-up/missingness and long-term dependence?Supplementary	The original selection is 90-day survivor-dependence data. Do not newly establish long-term permanent dependence, discharge independence, baseline chronic kidney disease/vulnerable groups or individual kidney recovery. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Dependence follow-up losses, later courses, vulnerable/subgroups and prespecified definitions are unverified. Existing content review remains incomplete.	90 days, survival conditions, discharge/long-term outcomes, vulnerable groups and observation loss	Proposal: Link dependence gaps across time/conditions. No new research, calculation or trial was performed.
22	Partly verified	Full text not readStored summary read	N22 · Efficacy comparison and presentation of stored materialCan findings be generalized to other patients, absolute indications or treatment choices?Required	The original is a historical comparison of severe-AKI strategies before absolute indications. Do not create individual judgments on absolute indications, treatment initiation/delay, dialysis modality/suitability or treatment recommendations for other diseases/severity levels. S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Direct dependence/safety materials for populations/strategies outside scope are unverified. Existing content review remains incomplete.	Severe-AKI study strategies, actual eligibility and questions outside scope	Proposal: Record population/strategy-specific evidence gaps. No new research, calculation or trial was performed.
23	Partly verified	Full text not readStored summary read	N23 · Efficacy comparison and presentation of stored materialWhat reading level applies to summaries, external reports/plans and URLs?Required	The complete preserved summary was read for production and marked 'summary read', with three original URLs/registry identifiers preserved. External papers/registries/plans/COI remain 'unread'; historical review/axis-evidence wording is not transferred into new reading/content review. S01 S02 S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. External access, abstracts/full papers/plans and link/click verification were not performed. Existing content review remains incomplete.	The complete preserved summary, three original URLs/registrations and unread external materials	Proposal: Record acquisition, reading and versions for each material. No new research, calculation or trial was performed.
24	Partly verified	Full text not readStored summary read	N24 · Efficacy comparison and presentation of stored materialHow are original Korean/English text, axis-evidence wording, empty values and dates preserved?Required	Preserve original Korean/English text, B0 axis-evidence wording, parent D34/Caution, false/empty values, 2026-08-26 and empty correction/deliberation values in the complete summary. Do not fill the subclaim D grade/note or absent points/status/axes with parent values. S01 S02 S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. At the historical production stage, verdict-prose translation, clinical-original review, grade changes, corrections and external updates were not performed. Existing content review remains incomplete.	Subclaim D, parent D34, 2026-08-26, false and empty arrays/strings	Proposal: Link original versions/dates with the selected independence question. No new research, calculation or trial was performed.
25	Partly verified	Full text not readStored summary read	N25 · Efficacy comparison and presentation of stored materialHow are condition preservation/application, case preparation and content review distinguished?Required	Condition preservation, freezing, application, case production and content review are separate records. Review of the existing content is incomplete; record counts are not totals of unique clinical trials/participants. S01 S02 S03	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Existing content review remains incomplete, and original clinical materials have not been newly verified. Existing content review remains incomplete.	Separate condition preservation/freezing/application, case production and incomplete content review	Proposal: Record condition/production versions and user correction history. No new research, calculation or trial was performed.

No items match your search or filter.

25 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Distinguish STARRT-AKI survivor 90-day dependence analysis denominators 814/815 from overall randomization/mortality denominators.
Ingredient, formulation and route: Historical early/standard KRT-initiation strategies before absolute indications in severe AKI; no initiation/delay instructions.
Dose: Not recorded
Comparator: Early versus standard strategy; different ELAIN/AKIKI mortality results provide context.
Measured outcome: Selected original 90-day KRT-independence question; the actual original report gives survivor dependence 85/814 versus 49/815, RR1.74.
Duration: Survivor-conditional dependence at 90 days, separate from ELAIN 90-day mortality, AKIKI 60-day survival and overall 90-day mortality.
Questions outside this scope: Calculating independence rates, independence RR, kidney-recovery rates, reciprocals or composite outcomes from dependence 10.4%/6.0% and RR1.74/CI; Calculating new survivor/missing/exclusion counts or rates from survivor 814/815, overall mortality 1465/1462 or 3019/2927; Establishing a 90-day survivor-conditional result as a causal effect in the whole population, permanent dependence, discharge independence or individual recovery; Repurposing positive ELAIN mortality or null AKIKI 60-day survival as direct values, replication or equivalence for 90-day independence; Repurposing historical null mortality RR1.00 wording as zero independence effect, equivalence or overall safety verification; Transferring centralized allocation/open design, a hard mortality endpoint or B0 wording to dependence-assessor blinding or content review here; Changing CIHR-Baxter partnership or Alere's in-kind measurement devices into free treatment equipment, absence of company relationships or independence verification; Creating new event counts/rates or established causality from possible hypotension, infection, bleeding or access complications; Extending severe-AKI study strategies into treatment initiation/delay, absolute-indication, procedure-modality/suitability or treatment instructions; Adding the same reports/trials/populations or different questions/groups/timepoints/denominators as new independent trials or total participants; Inheriting parent scores/axes, historical cross-checks, registration matches or full-text review accounts as subclaim values, current content review or external reading; New search/API use, numerical calculations, hypothetical numbers, new effects/CIs/grades, independent certification or treatment/suitability/administration guidance

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · ELAIN

PubMed

Material type: German single-center randomized trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: 39.3% versus 54.7%, HR 0.66, P=.03. Preserve only the relevant mortality result and original positive wording; do not repurpose them as independence rates, dependence, kidney-recovery effects or a new replication count.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 ELAIN/PMID27209269 reports 90-day mortality among 231 at one German center. Direct independence/dependence values are absent from this preserved summary; different early definitions, populations and endpoints do not verify replication of the selected independence question. S02 AKIKI/PMID27181456 reports 60-day survival among 620 randomized/619 analyzed at 31 French ICUs; timing/endpoints differ from selected 90-day KRT independence, and new dependence values/CI are not created. S03 STARRT-AKI/PMID32668114 is the same trial with 3019 randomized/2927 modified-ITT participants at 168 sites in 15 countries. Overall mortality denominators 1465/1462 differ from survivor-dependence denominators 814/815. Original B0 and prespecified mortality/registry-agreement wording are not transferred into dependence assessment/content review here. Across these records, do not sum the same reports, arms, people, timepoints, endpoints, other questions or denominators into new independent trials/participants. Report/material record counts are not unique clinical totals; unique-trial, participant and independent-replication totals remain null.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S02 · AKIKI

PubMed

Material type: Randomized trial in 31 French ICUs
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: No difference between early and delayed strategies. Preserve original null wording as the history of the mortality/survival question; do not fill 90-day independence/dependence values, equivalence or precision from it.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 ELAIN/PMID27209269 reports 90-day mortality among 231 at one German center. Direct independence/dependence values are absent from this preserved summary; different early definitions, populations and endpoints do not verify replication of the selected independence question. S02 AKIKI/PMID27181456 reports 60-day survival among 620 randomized/619 analyzed at 31 French ICUs; timing/endpoints differ from selected 90-day KRT independence, and new dependence values/CI are not created. S03 STARRT-AKI/PMID32668114 is the same trial with 3019 randomized/2927 modified-ITT participants at 168 sites in 15 countries. Overall mortality denominators 1465/1462 differ from survivor-dependence denominators 814/815. Original B0 and prespecified mortality/registry-agreement wording are not transferred into dependence assessment/content review here. Across these records, do not sum the same reports, arms, people, timepoints, endpoints, other questions or denominators into new independent trials/participants. Report/material record counts are not unique clinical totals; unique-trial, participant and independent-replication totals remain null.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S03 · STARRT-AKI

PubMed

Material type: Open-label randomized trial at 168 sites in 15 countries
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Preserve increased survivor 90-day dependence in the original direction: 85/814 (10.4%) versus 49/815 (6.0%), RR1.74 (95%CI1.24~2.43). Original 90-day mortality 43.9%/43.7% and RR1.00/CI/P are different outcomes. Dependence definitions/follow-up, survivor-conditional selection and denominator linkage are unverified; do not calculate independence rates, composites or new differences.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 ELAIN/PMID27209269 reports 90-day mortality among 231 at one German center. Direct independence/dependence values are absent from this preserved summary; different early definitions, populations and endpoints do not verify replication of the selected independence question. S02 AKIKI/PMID27181456 reports 60-day survival among 620 randomized/619 analyzed at 31 French ICUs; timing/endpoints differ from selected 90-day KRT independence, and new dependence values/CI are not created. S03 STARRT-AKI/PMID32668114 is the same trial with 3019 randomized/2927 modified-ITT participants at 168 sites in 15 countries. Overall mortality denominators 1465/1462 differ from survivor-dependence denominators 814/815. Original B0 and prespecified mortality/registry-agreement wording are not transferred into dependence assessment/content review here. Across these records, do not sum the same reports, arms, people, timepoints, endpoints, other questions or denominators into new independent trials/participants. Report/material record counts are not unique clinical totals; unique-trial, participant and independent-replication totals remain null.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 ELAIN/PMID27209269 reports 90-day mortality among 231 at one German center. Direct independence/dependence values are absent from this preserved summary; different early definitions, populations and endpoints do not verify replication of the selected independence question. S02 AKIKI/PMID27181456 reports 60-day survival among 620 randomized/619 analyzed at 31 French ICUs; timing/endpoints differ from selected 90-day KRT independence, and new dependence values/CI are not created. S03 STARRT-AKI/PMID32668114 is the same trial with 3019 randomized/2927 modified-ITT participants at 168 sites in 15 countries. Overall mortality denominators 1465/1462 differ from survivor-dependence denominators 814/815. Original B0 and prespecified mortality/registry-agreement wording are not transferred into dependence assessment/content review here. Across these records, do not sum the same reports, arms, people, timepoints, endpoints, other questions or denominators into new independent trials/participants. Report/material record counts are not unique clinical totals; unique-trial, participant and independent-replication totals remain null.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Does the selected KRT-independence question differ from the parent mortality verdict?

Required materials and conditions: Distinguish the subclaim D grade/note and absent points/status/axes from parent D34/axes
Conditions for verification: Original materials and analysis scope covering Distinguish the subclaim D grade/note and absent points/status/axes from parent D34/axes must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Distinguish the subclaim D grade/note and absent points/status/axes from parent D34/axes to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N02 · What values are provided for the original 'independence' question?

Required materials and conditions: Distinguish KRT independence from the survivor dependence actually reported
Conditions for verification: Original materials and analysis scope covering Distinguish KRT independence from the survivor dependence actually reported must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Distinguish KRT independence from the survivor dependence actually reported to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

N03 · What denominators are survivor 814/815 and mortality-analysis 1465/1462?

Required materials and conditions: Separate the survival condition/dependence analysis from the overall mortality analysis
Conditions for verification: Original materials and analysis scope covering Separate the survival condition/dependence analysis from the overall mortality analysis must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Separate the survival condition/dependence analysis from the overall mortality analysis to link the materials needed for the selected question with those currently available.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N04 · What comparison direction is represented by dependence RR1.74 and its CI?

Required materials and conditions: Distinguish early versus standard dependence RR/CI from independence/absolute effects
Conditions for verification: Original materials and analysis scope covering Distinguish early versus standard dependence RR/CI from independence/absolute effects must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Distinguish early versus standard dependence RR/CI from independence/absolute effects to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design; M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application

N05 · Is a survivor-conditional result the same as kidney recovery in all patients?

Required materials and conditions: Survivor selection, death as a competing event and randomized/conditional estimation
Conditions for verification: Original materials and analysis scope covering Survivor selection, death as a competing event and randomized/conditional estimation must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Survivor selection, death as a competing event and randomized/conditional estimation to link the materials needed for the selected question with those currently available.
Referenced methods: M08 §8.2.2 and M15 §15.3.1: in-house application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4: design-specific adaptation is in-house.

N06 · What were the actual STARRT-AKI population and initiation strategies?

Required materials and conditions: Severe AKI, early/standard initiation before absolute indications and eligibility/exclusions
Conditions for verification: Original materials and analysis scope covering Severe AKI, early/standard initiation before absolute indications and eligibility/exclusions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Severe AKI, early/standard initiation before absolute indications and eligibility/exclusions to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.1: detailed population conditions are in-house; M03 §3.2.2–3.2.3: reverse-direction labeling and test adaptation are in-house; M03 §3.2.3 and M08 §8.2.2–8.2.3: in-house application.

N07 · How do 3019 randomized and 2927 analyzed participants differ?

Required materials and conditions: Postrandomization ineligibility/consent withdrawal, denominators and modified ITT scope
Conditions for verification: Original materials and analysis scope covering Postrandomization ineligibility/consent withdrawal, denominators and modified ITT scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Postrandomization ineligibility/consent withdrawal, denominators and modified ITT scope to link the materials needed for the selected question with those currently available.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N08 · What were the 90-day dependence assessment and discontinuation/restart rules?

Required materials and conditions: Definitions of KRT status, assessment timing/duration and collection/follow-up
Conditions for verification: Original materials and analysis scope covering Definitions of KRT status, assessment timing/duration and collection/follow-up must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Definitions of KRT status, assessment timing/duration and collection/follow-up to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M08 Table 8.2.a and M03 §3.2.4: in-house application; M19 §19.1.2–19.2.4: detailed distinctions are in-house.

N09 · How does the open-label design relate to dependence assessment?

Required materials and conditions: Distinguish allocation concealment/openness from mortality/KRT decisions
Conditions for verification: Original materials and analysis scope covering Distinguish allocation concealment/openness from mortality/KRT decisions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Distinguish allocation concealment/openness from mortality/KRT decisions to link the materials needed for the selected question with those currently available.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

N10 · What was the prespecified endpoint hierarchy for dependence?

Required materials and conditions: Primary mortality, dependence/safety and multiplicity/prespecified analysis
Conditions for verification: Original materials and analysis scope covering Primary mortality, dependence/safety and multiplicity/prespecified analysis must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Primary mortality, dependence/safety and multiplicity/prespecified analysis to link the materials needed for the selected question with those currently available.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

N11 · Does overall 90-day mortality differ from the selected independence outcome?

Required materials and conditions: Separate context of original 643/1465, 639/1462 and RR1.00/CI/P
Conditions for verification: Original materials and analysis scope covering Separate context of original 643/1465, 639/1462 and RR1.00/CI/P must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Separate context of original 643/1465, 639/1462 and RR1.00/CI/P to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.3 and M15 §15.3.1–15.3.3: status separation is in-house; M15 §15.3.1–15.3.3: in-house application.

N12 · How do actual treatment exposure/crossover relate to dependence?

Required materials and conditions: Greater early-group exposure, indication-based standard initiation and actual pathways
Conditions for verification: Original materials and analysis scope covering Greater early-group exposure, indication-based standard initiation and actual pathways must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Greater early-group exposure, indication-based standard initiation and actual pathways to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.3 and M08 §8.2.2–8.2.3: in-house application; M08 §8.2.2 and M15 §15.3.1: in-house application; M19 §19.2: design-specific harm questions, with timing details in-house; M19 §19.2.2–19.2.4: design considerations, with detailed confounding records in-house.

N13 · Does ELAIN's positive mortality result directly answer 90-day independence?

Required materials and conditions: Context of 231 participants, one center, mortality 39.3/54.7% and HR/P
Conditions for verification: Original materials and analysis scope covering Context of 231 participants, one center, mortality 39.3/54.7% and HR/P must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Context of 231 participants, one center, mortality 39.3/54.7% and HR/P to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.1–4.6.2 and M15 §15.3.1: in-house application; M03 §3.2.4: in-house extension boundaries.

N14 · Does AKIKI 60-day survival directly answer 90-day independence?

Required materials and conditions: Scope of 620 randomized/619 analyzed, 31 ICUs and 60-day survival
Conditions for verification: Original materials and analysis scope covering Scope of 620 randomized/619 analyzed, 31 ICUs and 60-day survival must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Scope of 620 randomized/619 analyzed, 31 ICUs and 60-day survival to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.1–4.6.2 and M15 §15.3.1: in-house application; M03 §3.2.1–3.2.4: dosage, persistence and effect-modification details are in-house.

N15 · How do different early definitions and populations across the three trials relate?

Required materials and conditions: Institutions/patients/timing, strategy definitions and the history of conflicting original results
Conditions for verification: Original materials and analysis scope covering Institutions/patients/timing, strategy definitions and the history of conflicting original results must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Institutions/patients/timing, strategy definitions and the history of conflicting original results to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.6.1–4.6.2 and M15 §15.3.1: in-house application; M03 §3.2.1: detailed population conditions are in-house; M03 §3.2.2–3.2.3: reverse-direction labeling and test adaptation are in-house.

N16 · Are the same trial and parent mortality/independence questions and reports kept from being summed?

Required materials and conditions: Shared reports/trials/populations, different endpoints and units
Conditions for verification: Original materials and analysis scope covering Shared reports/trials/populations, different endpoints and units must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Shared reports/trials/populations, different endpoints and units to link the materials needed for the selected question with those currently available.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N17 · What were STARRT's mixed support and Alere's in-kind contribution?

Required materials and conditions: Distinguish public/industry partnership and in-kind measurement devices from actual roles/COI
Conditions for verification: Original materials and analysis scope covering Distinguish public/industry partnership and in-kind measurement devices from actual roles/COI must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Distinguish public/industry partnership and in-kind measurement devices from actual roles/COI to link the materials needed for the selected question with those currently available.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N18 · Does ELAIN/AKIKI support verify independence for the dependence question?

Required materials and conditions: Institutional/nonprofit support, French Ministry of Health and detailed roles
Conditions for verification: Original materials and analysis scope covering Institutional/nonprofit support, French Ministry of Health and detailed roles must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Institutional/nonprofit support, French Ministry of Health and detailed roles to link the materials needed for the selected question with those currently available.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N19 · Were registry IDs and prespecified independence/dependence analyses actually read?

Required materials and conditions: Original DRKS00004367, NCT01932190/02568722 identifiers and plans
Conditions for verification: Original materials and analysis scope covering Original DRKS00004367, NCT01932190/02568722 identifiers and plans must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Original DRKS00004367, NCT01932190/02568722 identifiers and plans to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N20 · How do KRT complications and dependence represent different harm information?

Required materials and conditions: Hypotension/infection/bleeding/access complications and actual event reports
Conditions for verification: Original materials and analysis scope covering Hypotension/infection/bleeding/access complications and actual event reports must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Why this condition is needed: This item distinguishes Hypotension/infection/bleeding/access complications and actual event reports to link the materials needed for the selected question with those currently available.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

N21 · What is the scope of survivor follow-up/missingness and long-term dependence?

Required materials and conditions: 90 days, survival conditions, discharge/long-term outcomes, vulnerable groups and observation loss
Conditions for verification: Original materials and analysis scope covering 90 days, survival conditions, discharge/long-term outcomes, vulnerable groups and observation loss must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Why this condition is needed: This item distinguishes 90 days, survival conditions, discharge/long-term outcomes, vulnerable groups and observation loss to link the materials needed for the selected question with those currently available.
Referenced methods: M19 §19.1.2–19.2.4 and M04 §4.6.3: in-house application; M19 §19.1.2–19.2.4: in-house application; M03 §3.2.1–3.2.4: dosage, persistence and effect-modification details are in-house.

N22 · Can findings be generalized to other patients, absolute indications or treatment choices?

Required materials and conditions: Severe-AKI study strategies, actual eligibility and questions outside scope
Conditions for verification: Original materials and analysis scope covering Severe-AKI study strategies, actual eligibility and questions outside scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Severe-AKI study strategies, actual eligibility and questions outside scope to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

N23 · What reading level applies to summaries, external reports/plans and URLs?

Required materials and conditions: The complete preserved summary, three original URLs/registrations and unread external materials
Conditions for verification: Original materials and analysis scope covering The complete preserved summary, three original URLs/registrations and unread external materials must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes The complete preserved summary, three original URLs/registrations and unread external materials to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N24 · How are original Korean/English text, axis-evidence wording, empty values and dates preserved?

Required materials and conditions: Subclaim D, parent D34, 2026-08-26, false and empty arrays/strings
Conditions for verification: Original materials and analysis scope covering Subclaim D, parent D34, 2026-08-26, false and empty arrays/strings must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Subclaim D, parent D34, 2026-08-26, false and empty arrays/strings to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N25 · How are condition preservation/application, case preparation and content review distinguished?

Required materials and conditions: Separate condition preservation/freezing/application, case production and incomplete content review
Conditions for verification: Original materials and analysis scope covering Separate condition preservation/freezing/application, case production and incomplete content review must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Separate condition preservation/freezing/application, case production and incomplete content review to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-10 · Public page/material version 1.0

The public page and data were prepared from the existing 25 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Does the selected KRT-independence question differ from the parent mortality verdict?

Current findings: The selected question is 'freedom from kidney replacement therapy at 90 days'; its original D grade/note says dependence among survivors was higher in the early group. Subclaim points, status and axes are absent; parent D34, Caution and the 90-day mortality verdict/axes are separate.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Do not fill absent subclaim values with parent values or create a new grade. Existing content review remains incomplete.
Reason for missing information: Do not fill absent subclaim values with parent values or create a new grade.
Required materials and conditions: Distinguish the subclaim D grade/note and absent points/status/axes from parent D34/axes
Materials to obtain first: Additional materials for the selected question or user feedback
Further research: Proposal: Separate the sources of the independence question and mortality verdict. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Distinguish the subclaim D grade/note and absent points/status/axes from parent D34/axes must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Distinguish the subclaim D grade/note and absent points/status/axes from parent D34/axes to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S03

N02 · What values are provided for the original 'independence' question?

Current findings: The original STARRT-AKI research description reports 90-day dependence among survivors as 85/814 (10.4%) versus 49/815 (6.0%), RR1.74 (95% CI1.24~2.43). Do not newly convert dependence values into independence rates, independence RR or recovery rates.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Direct independence events, proportions and definitions, and details of the original dependence endpoint, are unverified. Existing content review remains incomplete.
Reason for missing information: Direct independence events, proportions and definitions, and details of the original dependence endpoint, are unverified.
Required materials and conditions: Distinguish KRT independence from the survivor dependence actually reported
Materials to obtain first: 90-day dependence/independence definitions and original outcome/denominator tables
Further research: Proposal: Link the independence question with the reported dependence values. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Distinguish KRT independence from the survivor dependence actually reported must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Distinguish KRT independence from the survivor dependence actually reported to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

Related sources S03

N03 · What denominators are survivor 814/815 and mortality-analysis 1465/1462?

Current findings: Dependence 85/814 versus 49/815 uses the original survivor-conditional denominators. Mortality 643/1465 versus 639/1462 uses different analysis denominators; do not newly calculate survivors/missing counts from them to replace the dependence denominators.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Eligibility/exclusions, missingness/follow-up and reasons connecting the survivor-dependence denominators are unverified. Existing content review remains incomplete.
Reason for missing information: Eligibility/exclusions, missingness/follow-up and reasons connecting the survivor-dependence denominators are unverified.
Required materials and conditions: Separate the survival condition/dependence analysis from the overall mortality analysis
Materials to obtain first: Population flow by denominator, survival/dependence follow-up and original outcome tables
Further research: Proposal: Link the entire assigned/mortality population and survivor-conditional outcomes. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Separate the survival condition/dependence analysis from the overall mortality analysis must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Separate the survival condition/dependence analysis from the overall mortality analysis to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S03

N04 · What comparison direction is represented by dependence RR1.74 and its CI?

Current findings: Original survivor dependence increased from standard 6.0% to early 10.4%, RR1.74 (1.24~2.43). Do not turn it into an effect improving independence, mortality RR, a reciprocal or an absolute risk difference.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The original dependence P value, model/adjustment and event-definition/timing details are unverified. Existing content review remains incomplete.
Reason for missing information: The original dependence P value, model/adjustment and event-definition/timing details are unverified.
Required materials and conditions: Distinguish early versus standard dependence RR/CI from independence/absolute effects
Materials to obtain first: Dependence outcome tables and model/SAP
Further research: Proposal: Document the original comparison direction, interval and endpoint specification. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Distinguish early versus standard dependence RR/CI from independence/absolute effects must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Distinguish early versus standard dependence RR/CI from independence/absolute effects to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design; M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application

Related sources S03

N05 · Is a survivor-conditional result the same as kidney recovery in all patients?

Current findings: The original report concerns KRT dependence at 90 days among survivors. Do not calculate kidney recovery in all randomized patients, a pure causal dependence effect independent of death or a new survival/independence composite outcome.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Survivor-conditional selection, handling of death, composite/competing-event analyses and individual trajectories are unverified. Existing content review remains incomplete.
Reason for missing information: Survivor-conditional selection, handling of death, composite/competing-event analyses and individual trajectories are unverified.
Required materials and conditions: Survivor selection, death as a competing event and randomized/conditional estimation
Materials to obtain first: Time records of survival/death and KRT status, with the prespecified analysis plan
Further research: Proposal: Document conditional and whole-population outcomes separately. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Survivor selection, death as a competing event and randomized/conditional estimation must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Survivor selection, death as a competing event and randomized/conditional estimation to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2 and M15 §15.3.1: in-house application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4: design-specific adaptation is in-house.

Related sources S03

N06 · What were the actual STARRT-AKI population and initiation strategies?

Current findings: Original STARRT-AKI compares initiation strategies before absolute indications in severe acute kidney injury. The standard group also started when indications arose; this is a historical condition, with no treatment initiation/delay or suitability instructions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact severity/eligibility, early/standard timing and exclusion/concomitant-treatment details are unverified. Existing content review remains incomplete.
Reason for missing information: Exact severity/eligibility, early/standard timing and exclusion/concomitant-treatment details are unverified.
Required materials and conditions: Severe AKI, early/standard initiation before absolute indications and eligibility/exclusions
Materials to obtain first: Protocol, baseline/eligibility information and actual initiation records
Further research: Proposal: Link population and strategy conditions. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Severe AKI, early/standard initiation before absolute indications and eligibility/exclusions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Severe AKI, early/standard initiation before absolute indications and eligibility/exclusions to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1: detailed population conditions are in-house; M03 §3.2.2–3.2.3: reverse-direction labeling and test adaptation are in-house; M03 §3.2.3 and M08 §8.2.2–8.2.3: in-house application.

Related sources S03

N07 · How do 3019 randomized and 2927 analyzed participants differ?

Current findings: The original account states that STARRT-AKI randomized 3019 at 168 sites in 15 countries and analyzed 2927 by modified ITT after postrandomization ineligibility, consent withdrawal and other exclusions. Do not newly calculate exclusion counts/proportions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Arm-specific exclusions/missingness, dependence-analysis inclusion criteria and the entire follow-up path are unverified. Existing content review remains incomplete.
Reason for missing information: Arm-specific exclusions/missingness, dependence-analysis inclusion criteria and the entire follow-up path are unverified.
Required materials and conditions: Postrandomization ineligibility/consent withdrawal, denominators and modified ITT scope
Materials to obtain first: Participant flow, analysis populations/exclusions and consent/follow-up materials
Further research: Proposal: Link randomized, mortality and survivor analysis populations. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Postrandomization ineligibility/consent withdrawal, denominators and modified ITT scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Postrandomization ineligibility/consent withdrawal, denominators and modified ITT scope to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S03

N08 · What were the 90-day dependence assessment and discontinuation/restart rules?

Current findings: The original reports dependence among 90-day survivors. Do not newly attach definitions involving treatment on a specific day, a preceding period, discharge status or long-term dependence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Dependence/independence assessment rules, treatment discontinuation/restart and follow-up methods/missingness are unverified. Existing content review remains incomplete.
Reason for missing information: Dependence/independence assessment rules, treatment discontinuation/restart and follow-up methods/missingness are unverified.
Required materials and conditions: Definitions of KRT status, assessment timing/duration and collection/follow-up
Materials to obtain first: Dependence endpoint definitions, original collection/follow-up and status records
Further research: Proposal: Document KRT status and the timing/assessment specification. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Definitions of KRT status, assessment timing/duration and collection/follow-up must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Definitions of KRT status, assessment timing/duration and collection/follow-up to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M08 Table 8.2.a and M03 §3.2.4: in-house application; M19 §19.1.2–19.2.4: detailed distinctions are in-house.

Related sources S03

N09 · How does the open-label design relate to dependence assessment?

Current findings: The original describes centralized computer-generated allocation, an open-label design, a primary 90-day all-cause mortality endpoint and B0 evidence. Do not transfer the nature of mortality measurement to blinding of KRT continuation/discontinuation decisions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Dependence assessors/blinding, actual treatment decisions and follow-up procedures are unverified. Existing content review remains incomplete.
Reason for missing information: Dependence assessors/blinding, actual treatment decisions and follow-up procedures are unverified.
Required materials and conditions: Distinguish allocation concealment/openness from mortality/KRT decisions
Materials to obtain first: Allocation/dependence assessment, treatment-decision procedures and original records
Further research: Proposal: Link design with endpoint-specific measurement/decisions. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Distinguish allocation concealment/openness from mortality/KRT decisions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Distinguish allocation concealment/openness from mortality/KRT decisions to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources S03

N10 · What was the prespecified endpoint hierarchy for dependence?

Current findings: The original prespecified primary endpoint was all-cause mortality at 90 days. Do not upgrade survivor KRT dependence to the primary endpoint or newly assign a different independence objective or power.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Prespecification/hierarchy of the dependence endpoint, multiple comparisons and model/plan are unverified. Existing content review remains incomplete.
Reason for missing information: Prespecification/hierarchy of the dependence endpoint, multiple comparisons and model/plan are unverified.
Required materials and conditions: Primary mortality, dependence/safety and multiplicity/prespecified analysis
Materials to obtain first: Registration/protocol/SAP and endpoint hierarchy
Further research: Proposal: Link the primary timepoint/endpoint and secondary dependence analysis. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Primary mortality, dependence/safety and multiplicity/prespecified analysis must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Primary mortality, dependence/safety and multiplicity/prespecified analysis to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

Related sources S03

N11 · Does overall 90-day mortality differ from the selected independence outcome?

Current findings: The original mortality values are 643/1465 (43.9%) versus 639/1462 (43.7%), RR1.00 (.93~1.09), P=.92. Do not turn them into dependence incidence, zero independence effect, equivalence or conditional kidney-recovery verification.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Individual mortality/dependence linkage, joint estimation and precision details of the selected analysis are unverified. Existing content review remains incomplete.
Reason for missing information: Individual mortality/dependence linkage, joint estimation and precision details of the selected analysis are unverified.
Required materials and conditions: Separate context of original 643/1465, 639/1462 and RR1.00/CI/P
Materials to obtain first: Linked mortality/KRT-status tables and prespecified analysis
Further research: Proposal: Document hard mortality and survivor-conditional dependence separately. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Separate context of original 643/1465, 639/1462 and RR1.00/CI/P must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Separate context of original 643/1465, 639/1462 and RR1.00/CI/P to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.3 and M15 §15.3.1–15.3.3: status separation is in-house; M15 §15.3.1–15.3.3: in-house application.

Related sources S03

N12 · How do actual treatment exposure/crossover relate to dependence?

Current findings: The original study-condition description states that the early group had more treatment exposure and 90-day dependence. Do not arbitrarily fill exposure quantity/timing, procedure type/discontinuation or establish dependence causality from increased exposure alone.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Denominators/timing of actual exposure/crossover, procedure types, concomitant treatment and discontinuation/restart are unverified. Existing content review remains incomplete.
Reason for missing information: Denominators/timing of actual exposure/crossover, procedure types, concomitant treatment and discontinuation/restart are unverified.
Required materials and conditions: Greater early-group exposure, indication-based standard initiation and actual pathways
Materials to obtain first: Arm-specific actual/concomitant treatment and timed status records
Further research: Proposal: Link assigned strategies with actual exposure/dependence. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Greater early-group exposure, indication-based standard initiation and actual pathways must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Greater early-group exposure, indication-based standard initiation and actual pathways to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3 and M08 §8.2.2–8.2.3: in-house application; M08 §8.2.2 and M15 §15.3.1: in-house application; M19 §19.2: design-specific harm questions, with timing details in-house; M19 §19.2.2–19.2.4: design considerations, with detailed confounding records in-house.

Related sources S03

N13 · Does ELAIN's positive mortality result directly answer 90-day independence?

Current findings: The original ELAIN context is a German single-center trial of 231 reporting 90-day mortality of 39.3% versus 54.7%, HR.66, P=.03. Do not transfer it to direct values or a replication trial for the selected KRT-independence question.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. ELAIN 90-day independence/dependence definitions, values, denominators, CI and conditions are unverified in this preserved summary. Existing content review remains incomplete.
Reason for missing information: ELAIN 90-day independence/dependence definitions, values, denominators, CI and conditions are unverified in this preserved summary.
Required materials and conditions: Context of 231 participants, one center, mortality 39.3/54.7% and HR/P
Materials to obtain first: Original ELAIN KRT-status materials and protocol
Further research: Proposal: Separate mortality context from the selected independence endpoint. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Context of 231 participants, one center, mortality 39.3/54.7% and HR/P must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Context of 231 participants, one center, mortality 39.3/54.7% and HR/P to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.1–4.6.2 and M15 §15.3.1: in-house application; M03 §3.2.4: in-house extension boundaries.

Related sources S01

N14 · Does AKIKI 60-day survival directly answer 90-day independence?

Current findings: The original AKIKI context is no 60-day survival difference among 620 randomized/619 analyzed at 31 French ICUs. Do not change 60-day survival into 90-day KRT independence or a replicated dependence RR1.74.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. AKIKI independence/dependence timing, values, denominators and precision are unverified. Existing content review remains incomplete.
Reason for missing information: AKIKI independence/dependence timing, values, denominators and precision are unverified.
Required materials and conditions: Scope of 620 randomized/619 analyzed, 31 ICUs and 60-day survival
Materials to obtain first: Original AKIKI status/timing materials and plan
Further research: Proposal: Document differences in timing/endpoints. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Scope of 620 randomized/619 analyzed, 31 ICUs and 60-day survival must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Scope of 620 randomized/619 analyzed, 31 ICUs and 60-day survival to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.1–4.6.2 and M15 §15.3.1: in-house application; M03 §3.2.1–3.2.4: dosage, persistence and effect-modification details are in-house.

Related sources S02

N15 · How do different early definitions and populations across the three trials relate?

Current findings: The original account says early/delayed definitions and severity differed across trials. Do not certify ELAIN/AKIKI/STARRT mortality context as unique replication of the same dependence endpoint.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact strategy/eligibility/timing differences, dependence outcomes, effect modification and reasons for conflicting results are unverified. Existing content review remains incomplete.
Reason for missing information: Exact strategy/eligibility/timing differences, dependence outcomes, effect modification and reasons for conflicting results are unverified.
Required materials and conditions: Institutions/patients/timing, strategy definitions and the history of conflicting original results
Materials to obtain first: Trial-specific characteristics, KRT status and analysis plans
Further research: Proposal: Document relationships across different strategies/populations/endpoints. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Institutions/patients/timing, strategy definitions and the history of conflicting original results must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Institutions/patients/timing, strategy definitions and the history of conflicting original results to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.1–4.6.2 and M15 §15.3.1: in-house application; M03 §3.2.1: detailed population conditions are in-house; M03 §3.2.2–3.2.3: reverse-direction labeling and test adaptation are in-house.

Related sources S01 S02 S03

N16 · Are the same trial and parent mortality/independence questions and reports kept from being summed?

Current findings: This sheet's STARRT survivor data and parent mortality context are different conditions/endpoints of the same trial/population. Do not sum the three bibliographic entries, analysis denominators, timepoints or different questions into new independent trials/total participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Unique trial, participant and independent-replication totals have not been confirmed and remain unrecorded. Existing content review remains incomplete.
Reason for missing information: Unique clinical trial, participant and independent replication totals have not been verified and are not recorded.
Required materials and conditions: Shared reports/trials/populations, different endpoints and units
Materials to obtain first: Report↔trial↔population↔endpoint linkage materials, if provided
Further research: Proposal: Record shared/overlapping relationships separately. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Shared reports/trials/populations, different endpoints and units must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Shared reports/trials/populations, different endpoints and units to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources S01 S02 S03

N17 · What were STARRT's mixed support and Alere's in-kind contribution?

Current findings: The original describes two CIHR grants, CIHR-Baxter industry partnership, NHMRC, New Zealand HRC, NIHR HTA and Alere's in-kind Triage MeterPro devices for NGAL. Do not turn this into free treatment equipment, absence of company roles/COI or independence verification.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Support contracts, company/employee authors, analysis/manuscript decision rights and COI are unverified. Existing content review remains incomplete.
Reason for missing information: Support contracts, company/employee authors, analysis/manuscript decision rights and COI are unverified.
Required materials and conditions: Distinguish public/industry partnership and in-kind measurement devices from actual roles/COI
Materials to obtain first: Support/in-kind contributions, authorship/contributions/COI and research-role contracts
Further research: Proposal: Document funding/measurement-device support and actual roles. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Distinguish public/industry partnership and in-kind measurement devices from actual roles/COI must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Distinguish public/industry partnership and in-kind measurement devices from actual roles/COI to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S03

N18 · Does ELAIN/AKIKI support verify independence for the dependence question?

Current findings: Preserve original ELAIN institutional/nonprofit support and AKIKI French Ministry of Health funding. Funding names alone do not verify absence of product/company/employee authors or COI, or independent replication of the dependence endpoint.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Specific funding/product support, contributions, employees/COI and dependence outcomes are unverified. Existing content review remains incomplete.
Reason for missing information: Specific funding/product support, contributions, employees/COI and dependence outcomes are unverified.
Required materials and conditions: Institutional/nonprofit support, French Ministry of Health and detailed roles
Materials to obtain first: Original support/contribution/authorship/COI materials for each trial
Further research: Proposal: Separate each trial's funding from actual roles. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Institutional/nonprofit support, French Ministry of Health and detailed roles must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Institutional/nonprofit support, French Ministry of Health and detailed roles to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S01 S02

N19 · Were registry IDs and prespecified independence/dependence analyses actually read?

Current findings: Preserve each original registry ID. Do not transfer the historical account of the STARRT primary mortality endpoint agreeing with its registry into registry/plan reading here or prespecified dependence fulfillment.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Registry-change history, protocols/SAP and dependence hierarchy/missing-data plans remain unread. Existing content review remains incomplete.
Reason for missing information: Registry-change history, protocols/SAP and dependence hierarchy/missing-data plans remain unread.
Required materials and conditions: Original DRKS00004367, NCT01932190/02568722 identifiers and plans
Materials to obtain first: Registry/plan copies or user-provided materials
Further research: Proposal: Link endpoint-specific prespecified plans with report versions. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Original DRKS00004367, NCT01932190/02568722 identifiers and plans must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Original DRKS00004367, NCT01932190/02568722 identifiers and plans to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01 S02 S03

N20 · How do KRT complications and dependence represent different harm information?

Current findings: The original safety description discusses possible hypotension, infection, bleeding and vascular-access complications, alongside increased survivor dependence. Do not turn these into actual individual event counts/cause verification or zero overall risk.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Definitions/collection, denominators, exposure/timing, CI and relatedness of each complication are unverified. Existing content review remains incomplete.
Reason for missing information: Definitions/collection, denominators, exposure/timing, CI and relatedness of each complication are unverified.
Required materials and conditions: Hypotension/infection/bleeding/access complications and actual event reports
Materials to obtain first: Trial-specific safety tables and collection/exposure/follow-up materials
Further research: Proposal: Document dependence separately from other safety events. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Hypotension/infection/bleeding/access complications and actual event reports must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Hypotension/infection/bleeding/access complications and actual event reports to link the materials needed for the selected question with those currently available.
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

Related sources S03

N21 · What is the scope of survivor follow-up/missingness and long-term dependence?

Current findings: The original selection is 90-day survivor-dependence data. Do not newly establish long-term permanent dependence, discharge independence, baseline chronic kidney disease/vulnerable groups or individual kidney recovery.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Dependence follow-up losses, later courses, vulnerable/subgroups and prespecified definitions are unverified. Existing content review remains incomplete.
Reason for missing information: Dependence follow-up losses, later courses, vulnerable/subgroups and prespecified definitions are unverified.
Required materials and conditions: 90 days, survival conditions, discharge/long-term outcomes, vulnerable groups and observation loss
Materials to obtain first: KRT follow-up/missingness and long-term/subgroup plans
Further research: Proposal: Link dependence gaps across time/conditions. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering 90 days, survival conditions, discharge/long-term outcomes, vulnerable groups and observation loss must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes 90 days, survival conditions, discharge/long-term outcomes, vulnerable groups and observation loss to link the materials needed for the selected question with those currently available.
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Referenced methods: M19 §19.1.2–19.2.4 and M04 §4.6.3: in-house application; M19 §19.1.2–19.2.4: in-house application; M03 §3.2.1–3.2.4: dosage, persistence and effect-modification details are in-house.

Related sources S03

N22 · Can findings be generalized to other patients, absolute indications or treatment choices?

Current findings: The original is a historical comparison of severe-AKI strategies before absolute indications. Do not create individual judgments on absolute indications, treatment initiation/delay, dialysis modality/suitability or treatment recommendations for other diseases/severity levels.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Direct dependence/safety materials for populations/strategies outside scope are unverified. Existing content review remains incomplete.
Reason for missing information: Direct dependence/safety materials for populations/strategies outside scope are unverified.
Required materials and conditions: Severe-AKI study strategies, actual eligibility and questions outside scope
Materials to obtain first: Direct materials for the separate question, if provided
Further research: Proposal: Record population/strategy-specific evidence gaps. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Severe-AKI study strategies, actual eligibility and questions outside scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Severe-AKI study strategies, actual eligibility and questions outside scope to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

Related sources S03

N23 · What reading level applies to summaries, external reports/plans and URLs?

Current findings: The complete preserved summary was read for production and marked 'summary read', with three original URLs/registry identifiers preserved. External papers/registries/plans/COI remain 'unread'; historical review/axis-evidence wording is not transferred into new reading/content review.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. External access, abstracts/full papers/plans and link/click verification were not performed. Existing content review remains incomplete.
Reason for missing information: External access, abstracts/full papers/plans and link/click verification were not performed.
Required materials and conditions: The complete preserved summary, three original URLs/registrations and unread external materials
Materials to obtain first: User-provided materials and records of actual reading
Further research: Proposal: Record acquisition, reading and versions for each material. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering The complete preserved summary, three original URLs/registrations and unread external materials must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes The complete preserved summary, three original URLs/registrations and unread external materials to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03

N24 · How are original Korean/English text, axis-evidence wording, empty values and dates preserved?

Current findings: Preserve original Korean/English text, B0 axis-evidence wording, parent D34/Caution, false/empty values, 2026-08-26 and empty correction/deliberation values in the complete summary. Do not fill the subclaim D grade/note or absent points/status/axes with parent values.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. At the historical production stage, verdict-prose translation, clinical-original review, grade changes, corrections and external updates were not performed. Existing content review remains incomplete.
Reason for missing information: At the historical production stage, verdict-prose translation, clinical-original review, grade changes, corrections and external updates were not performed.
Required materials and conditions: Subclaim D, parent D34, 2026-08-26, false and empty arrays/strings
Materials to obtain first: Original correction materials or user comments
Further research: Proposal: Link original versions/dates with the selected independence question. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Subclaim D, parent D34, 2026-08-26, false and empty arrays/strings must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Subclaim D, parent D34, 2026-08-26, false and empty arrays/strings to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03

N25 · How are condition preservation/application, case preparation and content review distinguished?

Current findings: Condition preservation, freezing, application, case production and content review are separate records. Review of the existing content is incomplete; record counts are not totals of unique clinical trials/participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Existing content review remains incomplete, and original clinical materials have not been newly verified. Existing content review remains incomplete.
Reason for missing information: Review of the existing content is incomplete and clinical source material was not newly verified.
Required materials and conditions: Separate condition preservation/freezing/application, case production and incomplete content review
Materials to obtain first: User review feedback and additional preserved materials
Further research: Proposal: Record condition/production versions and user correction history. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Separate condition preservation/freezing/application, case production and incomplete content review must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Separate condition preservation/freezing/application, case production and incomplete content review to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03